Acura Pharmaceuticals to Develop Improved NEXAFED
July 15, 2013 at 06:36 AM EDT
Acura Pharmaceuticals (NASDAQ: ACUR ) today announced a second generation prototype formulation of its methamphetamine-resistant IMPEDE technology with pseudoephedrine hydrochloride yielded no measurable amount of crystal meth (the street name for the illicit drug methamphetamine hydrochloride) when processed in the direct conversion or one-pot method. Acura intends to immediately